UK markets closed

Addex Therapeutics Ltd (0QNV.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.1450+0.1450 (-32.22%)
At close: 05:27PM BST
Full screen
Previous close0.1800
Open0.1450
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.1450 - 0.1450
52-week range0.1450 - 0.1450
Volume6
Avg. volumeN/A
Market cap40,274
Beta (5Y monthly)1.76
PE ratio (TTM)N/A
EPS (TTM)-0.5260
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

    Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively. In his presentations, Mr. Dyer will pr

  • Globe Newswire

    Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

    CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financia

  • Globe Newswire

    Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

    Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric